Skip to main content
Skip to content
Case File
sd-10-EFTA01366401Dept. of JusticeOther

EFTA Document EFTA01366401

through the over-allotment option. • Stabilizing transactions involve bids to purchase units so long as the stabilizing bids do not exceed a specified maximum. Purchases to cover short positions and stabilizing purchases, as well as other purchases by the underwriters for their own accounts. may have the effect of preventing or retarding a decline in the market price of the units. They may also cause the price of the units to be higher than the price that would otherwise exist in the open

Date
Unknown
Source
Dept. of Justice
Reference
sd-10-EFTA01366401
Pages
1
Persons
0
Integrity
Loading PDF viewer...

Summary

through the over-allotment option. • Stabilizing transactions involve bids to purchase units so long as the stabilizing bids do not exceed a specified maximum. Purchases to cover short positions and stabilizing purchases, as well as other purchases by the underwriters for their own accounts. may have the effect of preventing or retarding a decline in the market price of the units. They may also cause the price of the units to be higher than the price that would otherwise exist in the open

Ask AI About This Document

0Share
PostReddit

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
through the over-allotment option. • Stabilizing transactions involve bids to purchase units so long as the stabilizing bids do not exceed a specified maximum. Purchases to cover short positions and stabilizing purchases, as well as other purchases by the underwriters for their own accounts. may have the effect of preventing or retarding a decline in the market price of the units. They may also cause the price of the units to be higher than the price that would otherwise exist in the open market in the absence of these transactions. The underwriters may conduct the see transactions in the over-the- counter market or otherwise. If the underwriters commence any of these transactions, they may discontinue them at any time. We estimate that our portion of the total expenses of this offering payable by us will be $750,000. excluding underwriting discounts and commissions. We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be requited to make because of any of those liabilities. We are not under any contractual obligation to engage any of the underwriters to provide any services for us after this offering, and have no present intent to do s0. However. any of the underwriters may introduce us to potential target businesses or assist us in raising additional capital in the future. If any of the underwriters provide services to us after this offering, we may pay such underwriter fair and reasonable fees that would be determined at that time in an arm's length negotiation: provided that no agreement will be entered into with any of the underwriters and no fees for such services will be paid to any of the underwriters prior to the date that is 90 days from the date of this prospectus. unless FINRA determines that such payment would not be deemed underwriters' compensation in connection with this offering and we may pay the underwriters of this offering or any entity with which they are affiliated a finder's fee or other compensation for services rendered to us in connection with the completion of a business combination. Sonic of the underwriters and their affiliates have engaged in, and may in the future engage in, investment banking and other commercial dealings in the ordinary• course of business 142 with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions. In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire. long and/or short positions in such securities and instruments. Notice to Prospective Investors in Australia No placement document, prospectus. product disclosure statement or other disclosure document has been lodged with the Australian Securities and Investments Commission ("ASIC"), in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the "Corporations Act"), and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. My offer in Australia of the shares may only be made to persons (the "Exempt Investors") who art "sophisticated investors" (within the meaning of section 708(8) of the Corporations Act), "professional investors" (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. The shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 61) of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6E) of thc Corporations Act. My person acquiring shares must observe such Australian on-sale restrictions. http://uww.sce.gov/Archivecledgar/datail643953AM0I21390015005425412015a2_globalparincr.htmr/27/2015 8:51:37 AM] CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) CONFIDENTIAL DB-SDNY-0057927 SONY GM_00204111 EFTA01366401

Technical Artifacts (1)

View in Artifacts Browser

Email addresses, URLs, phone numbers, and other technical indicators extracted from this document.

URLhttp://uww.sce.gov/Archivecledgar/datail643953AM0I21390015005425412015a2_globalparincr.htmr/27/2015

Related Documents (6)

Dept. of JusticeMar 11, 2011

FBI Bruce E Ivins Investigation

010347Anthrax Page 1 of 1274 (Rev. 01-31-2003) FEDERAL BUREAU OF INVESTIGATION o Precedence: To: From: ROUTINE Date: 02/01/2007 Washington Field Washington Field Squad AMX-1/~VRA Contact: SAl ~--~~--------------------------~ b6 Approved By: Drafted By: Case ID #: 279A-WF-222936 ~79A-WF-222936-BEI (Pending) .. {{t;1%l.O (Pending)-1 279A-WF-222936-BEI-FISUR (Pending) -/ Title: AMERITHRAX; MAJOR CASE 184 ....?,-;-~"$'- Synopsis: Opening of sub-files for the'--'.:9a'ptioned matter. D

1274p
Dept. of JusticeOtherUnknown

EFTA Document EFTA01427451

Form S-1 S-1 1 d734898ds1.htm FORM S-1 Table of Contents As filed with the Securities and Exchange Commission on June 10, 2015 Registration No. 333UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BLUE BUFFALO PET PRODUCTS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) 2047 (Primary Standard Industrial Class

369p
Dept. of JusticeMar 11, 2011

FBI USAMRID Investigation

011621Anthrax Page 1 of 1446 o I 2792\-WF-222936-'-USAMRIID - \\OC o I [he followijg investigation was conducted by Special Agent (SA)_ _of the federal Bureau of Investigation (FBI) on February 24, 2005: ? The United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Keycard Access records from 1998 through 2002 were queried f r v' ? ? ? scientist nd visitin scient'st both ?rom the who have p eviously been identified as visiting USAMRIID circa May 1998. ;11 available

1446p
Dept. of JusticeAug 22, 2017

20 Sent May through August 2016 _Redacted.pdf

Kristen M. Simkins From: Sent: To: Subject: Attachments: Richard C. Smith Thursday, September 01, 2016 9:20 AM Amy Rumbel; Brenda A. McKinley; Danielle Minarchick; Denise L. Elbell; Eileen B. Mckinney; Ellen Struble; Faith Ryan; Gene Lauri; Gene Lauri; Harvery Haack; Jennifer Crane; Peg Dobrinska; Peter Shull; Richard C. Smith; Sara Mays; Tom Young; Wendy Vinhage FW: Life Skills Meeting 8.24.16 Reentry Life Skills Subcommittee Meeting Notes.docx Life Skills Committee: Please find attached not

1370p
Dept. of JusticeAug 22, 2017

15 July 7 2016 - July 17 2016 working progress_Redacted.pdf

Kristen M. Simkins From: Sent: To: Cc: Subject: Irons, Janet < Tuesday, July 12, 2016 10:47 AM Richard C. Smith     Hello Warden Smith,     mother is anxious to hear the results of your inquiry into her daughter's health.   I'd be grateful if you could  email or call me at your earliest convenience.  I'm free today after 2 p.m.  Alternatively, we could meet after the Prison  Board of Inspectors Meeting this coming Thursday.    Best wishes,    Janet Irons    1 Kristen M. Simkins From: Sent:

1196p
Dept. of JusticeAug 22, 2017

17 August 16 through August 31 2016_Redacted.pdf

Kristen M. Simkins From: Sent: To: Subject: Attachments: Juan Mendez Tuesday, August 16, 2016 1:10 AM Brenda A. McKinley; C. Kay Woodring; Caitlyn D. Neff; Danielle Minarchick; Eric A. Lockridge; Jeffrey T. Hite; Jonathan M. Millinder; Julie A. Simoni; Kevin T. Jeirles; Larry L. Lidgett; Lee R. Sheaffer; Lorinda L. Brown; Matthew T. Fisher; Melanie L. Gordon; Michael S. Woods; Richard C. Smith; Stephanie D. McGhee; Thomas S. Allen, Jr.; Walter E. Jeirles Calendar and Status Report 8/16/2016 20

1846p

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.

Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.